Axelopran
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. (June 2015) (Learn how and when to remove this template message) |
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide
|
|
| Identifiers | |
| CAS Number | 949904-48-7 949904-50-1 (sulfate) |
| ATC code | none |
| PubChem | CID 67156338 |
| ChemSpider | 31444004 |
| Chemical data | |
| Formula | C26H39N3O4 |
| Molar mass | 457.60556 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma for the treatment of opioid-induced constipation. It acts as a potent, selective, and peripherally-restricted μ-, κ-, and δ-opioid receptor antagonist, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract in vivo, and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration.[1]
See also[edit]
References[edit]
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
